Core Scientific, Inc./tx
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
CORZ$12.72+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except par value)
| March 31,2026 | December 31,2025 | |
|---|---|---|
| Assets · (Unaudited) | ||
| Current Assets: | ||
| Cash and cash equivalents | $1,005,148 | $311,378 |
| Restricted cash, current portion | 60,244 | — |
| Digital assets | 37,312 | 222,000 |
| Customer funding receivable and other current assets | 352,128 | 362,159 |
| Total Current Assets | 1,454,832 | 895,537 |
| Property, plant and equipment, net | 1,344,924 | 1,293,299 |
| Operating lease right-of-use assets | 105,986 | 108,484 |
| Restricted cash, net of current portion | 80,593 | — |
| Other noncurrent assets | 83,229 | 50,324 |
| Total Assets | $3,069,564 | $2,347,644 |
| Liabilities and Stockholders’ Deficit | ||
| Current Liabilities: | ||
| Accounts payable | $218,857 | $126,106 |
| Accrued expenses | 364,479 | 511,957 |
| Deferred revenue | 219,555 | 127,561 |
| Notes payable, current portion | 993,944 | — |
| Warrant liabilities, current portion | 844,752 | — |
| Other current liabilities | 20,196 | 15,777 |
| Total Current Liabilities | 2,661,783 | 781,401 |
| Convertible and other notes payable, net of current portion | 1,061,651 | 1,060,325 |
| Warrant liabilities, net of current portion | 116,495 | 936,107 |
| Deferred revenue, net of current portion | 434,672 | 428,290 |
| Other noncurrent liabilities | 100,649 | 104,261 |
| Total Liabilities | 4,375,250 | 3,310,384 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ Deficit: | ||
| Preferred stock; $0.00001 par value; 2,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock; $0.00001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; 316,949 and 314,231 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 3 | 3 |
| Additional paid-in capital | 3,188,202 | 3,183,960 |
| Accumulated deficit | (4,493,891) | (4,146,703) |
| Total Stockholders’ Deficit | (1,305,686) | (962,740) |
| Total Liabilities and Stockholders’ Deficit | $3,069,564 | $2,347,644 |
Certain prior year amounts have been reclassified for consistency with the current year presentation.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.